List of Figures
Figure 1: HNC Therapeutics Market, Australia, Estimated Age-Specific Incidence and Mortality Rates for HNC, by Sex, 2017 12
Figure 2: HNC Therapeutics Market, Australia, Five-Year Relative Survival from HNC by Sex, 1984–2013 12
Figure 3: HNC Therapeutics Market, Treatment Algorithm for HNC (Excluding Nasopharyngeal and Thyroid Cancer) 32
Figure 4: HNC Therapeutics Market, Treatment Algorithm for Nasopharyngeal Cancer and Thyroid Cancer 33
Figure 5: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 53
Figure 6: HNC Therapeutics Market, Global, Pipeline, 2017 59
Figure 7: HNC Therapeutics Market, Global, Pipeline by Molecular Target, 2017 61
Figure 8: HNC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017 62
Figure 9: HNC Therapeutics Market, APAC, Imfinzi Forecast ($m), 2019–2023 65
Figure 10: HNC Therapeutics Market, APAC, Durvalumab plus Tremelimumab Forecast ($m), 2019–2023 66
Figure 11: HNC Therapeutics Market, APAC, Gilotrif/Giotrif/Xovoltib Forecast ($m), 2020–2023 68
Figure 12: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 71
Figure 13: HNC Therapeutics Market, Competitor Matrix for HNC Marketed and Pipeline Products, 2017 72
Figure 14: HNC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2016 74
Figure 15: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016 75
Figure 16: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016 76
Figure 17: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016 77
Figure 18: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2016 78
Figure 19: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006–2016 79
Figure 20: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006–2016 80
Figure 21: HNC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2016 81
Figure 22: HNC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006–2016 82
Figure 23: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 83
Figure 24: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 83
Figure 25: HNC Therapeutics Market, APAC, Treatment Patterns (‘000), 2016–2023 86
Figure 26: HNC Therapeutics Market, APAC, Market Size ($m), 2016–2023 87
Figure 27: HNC Therapeutics Market, India, Treatment Patterns (‘000), 2016–2023 88
Figure 28: HNC Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023 89
Figure 29: HNC Therapeutics Market, India, Market Size ($m), 2016–2023 90
Figure 30: HNC Therapeutics Market, China, Treatment Patterns (‘000), 2016–2023 91
Figure 31: HNC Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023 92
Figure 32: HNC Therapeutics Market, China, Market Size ($m), 2016–2023 93
Figure 33: HNC Therapeutics Market, Australia, Treatment Patterns (‘000), 2016–2023 94
Figure 34: HNC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023 95
Figure 35: HNC Therapeutics Market, Australia, Market Size ($m), 2016–2023 96
Figure 36: HNC Therapeutics Market, South Korea, Treatment Patterns (‘000), 2016–2023 98
Figure 37: HNC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023 99
Figure 38: HNC Therapeutics Market, South Korea, Market Size ($m), 2016–2023 100
Figure 39: HNC Therapeutics Market, Japan, Treatment Patterns (‘000), 2016–2023 101
Figure 40: HNC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023 102
Figure 41: HNC Therapeutics Market, Japan, Market Size ($m), 2016–2023 103
Figure 42: HNC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017 109
Figure 43: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006–2017 110
Figure 44: HNC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2017 111
Figure 45: HNC Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2017 112
Figure 46: HNC Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–2017 113
Figure 47: HNC Therapeutics Market, Global, Co-development Deals by Region, 2006–2017 115
Figure 48: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006–2017 116
Figure 49: HNC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2017 117
Figure 50: HNC Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2017 118
Figure 51: HNC Therapeutics Market, Global, Co-development Deals by by Molecular Target and Aggregate Deal Value ($m), 2006–2017 119